Casdatifan for Healthy Subjects

This trial tests how the body processes a new drug called casdatifan. The study compares the effects of taking one 100 mg tablet versus four 25 mg tablets and examines whether eating affects the drug's efficacy when taken as four 25 mg tablets. It is open to healthy non-smokers who weigh at least 45 kg and can easily swallow multiple tablets. Participants should not have a history of asthma, serious food allergies, or certain neurological issues. As a Phase 1 trial, participants will be among the first to help researchers understand how this new treatment works in people.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that casdatifan is generally safe and well-tolerated. Earlier studies found that both healthy individuals and patients with conditions like cancer experienced similar safety outcomes. No unexpected safety issues emerged, and the treatment was manageable at various doses. Some studies noted that casdatifan was well-tolerated, even in patients with kidney cancer. However, a smaller number of participants experienced serious side effects, such as anemia (low red blood cell count) and hypoxia (low oxygen levels). Overall, the treatment appears fairly safe for most people based on the available data.¹²³⁴⁵

Researchers are excited about casdatifan because it offers a potentially new approach to managing conditions that involve inflammation and immune response. Unlike current treatments that primarily use steroids or NSAIDs to control inflammation, casdatifan is designed to work by targeting specific pathways in the immune system, potentially offering more precise control with fewer side effects. This trial explores different dosages and conditions, such as fasting and fed states, to understand how the body absorbs the drug, which could lead to more effective treatment regimens.

Research has shown that casdatifan may be promising for treating kidney cancer. Studies found that patients lived over 15 months on average without their cancer worsening. The treatment worked for 25% to 45% of patients, depending on the dose. This suggests that casdatifan could help slow cancer progression and improve patient health. While the main focus has been on kidney cancer, these results suggest casdatifan might also be useful for treating other types of cancer.